{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:09:07Z","timestamp":1694329747531},"reference-count":24,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.3892\/ijo.2014.2468","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T04:49:43Z","timestamp":1401166183000},"page":"532-540","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer"],"prefix":"10.3892","volume":"45","author":[{"given":"IRENE","family":"ZINONOS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KE-WANG","family":"LUO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AGATHA","family":"LABRINIDIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VASILIOS","family":"LIAPIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHELLEY","family":"HAY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VASILIOS","family":"PANAGOPOULOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARK","family":"DENICHILO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHUN-HAY","family":"KO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GRACE GAR-LEE","family":"YUE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CLARA BIK-SAN","family":"LAU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WENDY","family":"INGMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VLADIMIR","family":"PONOMAREV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GERALD J.","family":"ATKINS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAVID M.","family":"FINDLAY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREW C.W.","family":"ZANNETTINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREAS","family":"EVDOKIOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"key20180107181843_b1-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107181843_b2-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"key20180107181843_b3-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: advancing treatment and prevention","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"key20180107181843_b4-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"key20180107181843_b5-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1185\/03007995.2010.533162","article-title":"Understanding and optimizing bone health in breast cancer","volume":"26","author":"Guise","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key20180107181843_b6-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"key20180107181843_b7-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107181843_b8-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"key20180107181843_b9-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: from primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett"},{"key":"key20180107181843_b10-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"key20180107181843_b11-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-04-2033","article-title":"Osteoprotegerin in prostate cancer bone metastasis","volume":"65","author":"Corey","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107181843_b12-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-05-3119","article-title":"Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically","volume":"66","author":"Fisher","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107181843_b13-ijo-45-02-0532","first-page":"2977","article-title":"Serum osteoprotegerin levels are increased in patients with advanced prostate cancer","volume":"7","author":"Brown","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107181843_b14-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cncr.21978","article-title":"Expression of RANKL\/RANK\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation","volume":"107","author":"Chen","year":"2006","journal-title":"Cancer"},{"key":"key20180107181843_b15-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jbmr.244","article-title":"Anticancer efficacy of Apo2L\/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo","volume":"26","author":"Zinonos","year":"2011","journal-title":"J Bone Miner Res"},{"key":"key20180107181843_b16-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-08-2444","article-title":"Apo2L\/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107181843_b17-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/0008-5472.CAN-09-4291","article-title":"Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases","volume":"70","author":"Endo-Munoz","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107181843_b18-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canlet.2013.07.024","article-title":"Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models","volume":"339","author":"Luo","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107181843_b19-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"key20180107181843_b20-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"key20180107181843_b21-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"key20180107181843_b22-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"key20180107181843_b23-ijo-45-02-0532","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"key20180107181843_b24-ijo-45-02-0532","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2014.2468\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T13:22:21Z","timestamp":1515331341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2014.2468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,5,27]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.3892\/ijo.2014.2468"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2014.2468","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}